Antidepressant prescribing practices for the treatment of children and adolescents

Supriya K. Bhatia, Amy J. Rezac, Benedetto Vitiello, Michael Allen Sitorius, Bruce A. Buehler, Christopher J Kratochvil

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: This study evaluates pediatric antidepressant prescribing practices of Nebraska clinicians. Methods: Surveys were sent in July, 2005, to 1,521 prescribing clinicians throughout Nebraska to assess pediatric antidepressant use along with any practice changes following the U.S. Food and Drug Administration (FDA) "black box" warning issued in October, 2004. Results: Over half (n 866) of the clinicians responded to the survey, of which 96.8% reported awareness of the FDA "black box" warning. Of the respondents, 76.9% (n = 666) were prescribing antidepressants to children and/or adolescents. Clinicians reported decreased prescribing frequency for both children (15.5%) and adolescents (36.6%), with 36% having increased referrals to specialists. While 31.9% reported seeing patients more frequently upon initiation of antidepressants, only 7.5% reported weekly visits for the first month of treatment, as recommended by the FDA. Over one fifth (21.9%) reported a caregiver or patient had refused antidepressant medication treatment due to the FDA's warning. Conclusion: Clinicians in Nebraska report changes in clinical practice due to the issuance of the FDA "black box" warning, with a decrease in prescribing antidepressants to pediatric patients and an increase in referrals to specialists. Although awareness of the FDA's warning was evident among clinicians and patients, adherence to recommended guidelines was low.

Original languageEnglish (US)
Pages (from-to)70-80
Number of pages11
JournalJournal of Child and Adolescent Psychopharmacology
Volume18
Issue number1
DOIs
StatePublished - Feb 1 2008

Fingerprint

Antidepressive Agents
Drug Labeling
United States Food and Drug Administration
Pediatrics
Therapeutics
Referral and Consultation
Patient Compliance
Caregivers
Guidelines
Surveys and Questionnaires

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Antidepressant prescribing practices for the treatment of children and adolescents. / Bhatia, Supriya K.; Rezac, Amy J.; Vitiello, Benedetto; Sitorius, Michael Allen; Buehler, Bruce A.; Kratochvil, Christopher J.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 18, No. 1, 01.02.2008, p. 70-80.

Research output: Contribution to journalArticle

@article{ee8d0929a8e54bae9ab5ec699a41b242,
title = "Antidepressant prescribing practices for the treatment of children and adolescents",
abstract = "Objective: This study evaluates pediatric antidepressant prescribing practices of Nebraska clinicians. Methods: Surveys were sent in July, 2005, to 1,521 prescribing clinicians throughout Nebraska to assess pediatric antidepressant use along with any practice changes following the U.S. Food and Drug Administration (FDA) {"}black box{"} warning issued in October, 2004. Results: Over half (n 866) of the clinicians responded to the survey, of which 96.8{\%} reported awareness of the FDA {"}black box{"} warning. Of the respondents, 76.9{\%} (n = 666) were prescribing antidepressants to children and/or adolescents. Clinicians reported decreased prescribing frequency for both children (15.5{\%}) and adolescents (36.6{\%}), with 36{\%} having increased referrals to specialists. While 31.9{\%} reported seeing patients more frequently upon initiation of antidepressants, only 7.5{\%} reported weekly visits for the first month of treatment, as recommended by the FDA. Over one fifth (21.9{\%}) reported a caregiver or patient had refused antidepressant medication treatment due to the FDA's warning. Conclusion: Clinicians in Nebraska report changes in clinical practice due to the issuance of the FDA {"}black box{"} warning, with a decrease in prescribing antidepressants to pediatric patients and an increase in referrals to specialists. Although awareness of the FDA's warning was evident among clinicians and patients, adherence to recommended guidelines was low.",
author = "Bhatia, {Supriya K.} and Rezac, {Amy J.} and Benedetto Vitiello and Sitorius, {Michael Allen} and Buehler, {Bruce A.} and Kratochvil, {Christopher J}",
year = "2008",
month = "2",
day = "1",
doi = "10.1089/cap.2007.0049",
language = "English (US)",
volume = "18",
pages = "70--80",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Antidepressant prescribing practices for the treatment of children and adolescents

AU - Bhatia, Supriya K.

AU - Rezac, Amy J.

AU - Vitiello, Benedetto

AU - Sitorius, Michael Allen

AU - Buehler, Bruce A.

AU - Kratochvil, Christopher J

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Objective: This study evaluates pediatric antidepressant prescribing practices of Nebraska clinicians. Methods: Surveys were sent in July, 2005, to 1,521 prescribing clinicians throughout Nebraska to assess pediatric antidepressant use along with any practice changes following the U.S. Food and Drug Administration (FDA) "black box" warning issued in October, 2004. Results: Over half (n 866) of the clinicians responded to the survey, of which 96.8% reported awareness of the FDA "black box" warning. Of the respondents, 76.9% (n = 666) were prescribing antidepressants to children and/or adolescents. Clinicians reported decreased prescribing frequency for both children (15.5%) and adolescents (36.6%), with 36% having increased referrals to specialists. While 31.9% reported seeing patients more frequently upon initiation of antidepressants, only 7.5% reported weekly visits for the first month of treatment, as recommended by the FDA. Over one fifth (21.9%) reported a caregiver or patient had refused antidepressant medication treatment due to the FDA's warning. Conclusion: Clinicians in Nebraska report changes in clinical practice due to the issuance of the FDA "black box" warning, with a decrease in prescribing antidepressants to pediatric patients and an increase in referrals to specialists. Although awareness of the FDA's warning was evident among clinicians and patients, adherence to recommended guidelines was low.

AB - Objective: This study evaluates pediatric antidepressant prescribing practices of Nebraska clinicians. Methods: Surveys were sent in July, 2005, to 1,521 prescribing clinicians throughout Nebraska to assess pediatric antidepressant use along with any practice changes following the U.S. Food and Drug Administration (FDA) "black box" warning issued in October, 2004. Results: Over half (n 866) of the clinicians responded to the survey, of which 96.8% reported awareness of the FDA "black box" warning. Of the respondents, 76.9% (n = 666) were prescribing antidepressants to children and/or adolescents. Clinicians reported decreased prescribing frequency for both children (15.5%) and adolescents (36.6%), with 36% having increased referrals to specialists. While 31.9% reported seeing patients more frequently upon initiation of antidepressants, only 7.5% reported weekly visits for the first month of treatment, as recommended by the FDA. Over one fifth (21.9%) reported a caregiver or patient had refused antidepressant medication treatment due to the FDA's warning. Conclusion: Clinicians in Nebraska report changes in clinical practice due to the issuance of the FDA "black box" warning, with a decrease in prescribing antidepressants to pediatric patients and an increase in referrals to specialists. Although awareness of the FDA's warning was evident among clinicians and patients, adherence to recommended guidelines was low.

UR - http://www.scopus.com/inward/record.url?scp=39749159638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749159638&partnerID=8YFLogxK

U2 - 10.1089/cap.2007.0049

DO - 10.1089/cap.2007.0049

M3 - Article

C2 - 18294090

AN - SCOPUS:39749159638

VL - 18

SP - 70

EP - 80

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1

ER -